The application is designed to evaluate the role of the IL-2/IL-2R pathway, found to be ubiquitously expressed in malignant and normal tissues, in growth regulation of oral squamous cell carcinoma (OSCC) cells. The studies completed in the last three years indicate that IL-2 is produced, but not secreted, at levels detectable in ELISA by human OSCC and that it functions as a growth hormone and apoptosis protection factor in tumor cells. These cells also express functional IL-2R. Exogenous IL-2 binding at nM concentrations to its receptor inhibits growth of OSCC cell lines by inducing cell cycle arrest in G0/G1. The mechanisms responsible for growth-promoting signals mediated by endogenous IL-2 vs. negative growth signals delivered by exogenous IL-2 will be investigated in vitro and in vivo, using both OSCC cell lines and xenograft model of OSCC immunosuppressed BALB/c nude mice established in the Prinicpal Investigator's laboratory. They hypothesis to be tested is that endogenous IL-2 acts as growth-promoting factor in OSCC cells by down- regulating expression of CDK cell cycle inhibitors, while exogenous IL-2 interferes with growth by disrupting this essential endogenous pathway. Expression, activity and transcriptional regulation of Cyclins, CDKs and CDK inhibitors and Rb protein phosphorylation levels in OSCC cells treated with antisense IL-2 or antisense IL-2Rbeta and in untreated control cells will be evaluated and related to growth in vivo in OSCC- xenografted nude mice. Mechanisms of IL-2 mediated protection of tumor cells from apoptosis possibly by regulation of the state of Rb protein phosphorylation will be probed. Intracellular pathways of IL-2 mediated protection of tumor cells from apoptosis possibly by regulation of the stat of Rb protein phosphorylation will be probed. Intracellular pathways of IL-2 and IL-2r processing, localization and trafficking in tumor cells will be studied by confocal and immunogold electron microscopy to determine whether exogenous vs. endogenous IL-2 pathways operate in distinct cellular compartments. Understanding of the regulatory role of the IL-2/IL-2R pathway in tumor cells provides opportunities for novel therapeutic interventions in OSCC based not only on arrest of tumor growth by exogenous IL-2 but also on the use of pharmacologic and/or biologic agents known to be able to disrupt the IL- 2 pathway.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA063513-06
Application #
6172148
Study Section
Oral Biology and Medicine Subcommittee 1 (OBM)
Program Officer
Yovandich, Jason L
Project Start
1994-06-10
Project End
2002-04-30
Budget Start
2000-05-01
Budget End
2002-04-30
Support Year
6
Fiscal Year
2000
Total Cost
$218,573
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kuhn, Deborah J; Smith, David M; Pross, Seth et al. (2003) Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem 89:824-36
Whiteside, Theresa L; Gambotto, Andrea; Albers, Andreas et al. (2002) Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo. Proc Natl Acad Sci U S A 99:9415-20
Reichert, T E; Nagashima, S; Kashii, Y et al. (2000) Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 19:514-25
Reichert, T E; Kashii, Y; Stanson, J et al. (1999) The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. Br J Cancer 81:822-31
Kashii, Y; Giorda, R; Herberman, R B et al. (1999) Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 163:5358-66
Nagashima, S; Mailliard, R; Kashii, Y et al. (1998) Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91:3850-61
Lang, S; Vujanovic, N L; Wollenberg, B et al. (1998) Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur J Immunol 28:780-6
Whiteside, T L; Sung, M W; Nagashima, S et al. (1998) Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. Clin Cancer Res 4:1135-45
Reichert, T E; Watkins, S; Stanson, J et al. (1998) Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem 46:603-11
Reichert, T E; Rabinowich, H; Johnson, J T et al. (1998) Mechanisms responsible for signaling and functional defects. J Immunother 21:295-306

Showing the most recent 10 out of 21 publications